Table 1.

Major clinical trials testing the effects of single antiplatelet therapy in primary prevention

	Aspirin dose (mg)	Endpoint	Conclusions
Baigent et al11	50–500	CV and hemorrhagic events	No ASA benefits versus placebo
Wolff et al12	75–500	CV and hemorrhagic events	Risk reduction for MI in men and stroke in women, increased serious bleeding risk
Sacco et al14	100	CV death, stroke, MI	No benefit in diabetics, slight advantage in diabetes plus one risk factor
Ridker et al15	50	CV death, stroke, MI	No significant advantage
Berger et al17	75–500	CV and hemorrhagic events	No ASA benefits versus placebo
De Berardis et al18	75–325	CV death, stroke, MI	MI reduction in men, no survival benefit
Younis et al19	75–325	CV and hemorrhagic events	No ASA benefits versus placebo

Abbreviations: CV, cardiovascular; ASA, aspirin; MI, myocardial infarction.